Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on α-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomas in Vitro
| العنوان: | Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on α-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomas in Vitro |
|---|---|
| المؤلفون: | Angelo Margutti, Michael D. Culler, Roberto Padovani, Daniela Piccin, Maria Chiara Zatelli, John E. Taylor, Ettore C. degli Uberti, Luigi Cavazzini, Arianna Bottoni, Massimo Scanarini, Maria Rosaria Ambrosio |
| المصدر: | The Journal of Clinical Endocrinology & Metabolism. 89:5181-5188 |
| بيانات النشر: | The Endocrine Society, 2004. |
| سنة النشر: | 2004 |
| مصطلحات موضوعية: | Adenoma, Adult, Male, medicine.medical_specialty, Cell Survival, cells, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, In Vitro Techniques, Biochemistry, Endocrinology, hemic and lymphatic diseases, Internal medicine, Chromogranins, Tumor Cells, Cultured, medicine, Humans, Somatostatin receptor 2, Pituitary Neoplasms, Somatostatin receptor 1, Secretion, RNA, Messenger, Receptors, Somatostatin, Viability assay, Receptor, neoplasms, Aged, biology, Somatostatin receptor, Biochemistry (medical), Chromogranin A, hemic and immune systems, Middle Aged, Immunohistochemistry, Somatostatin, biology.protein, Female, biological phenomena, cell phenomena, and immunity |
| الوصف: | Somatostatin (SRIF) analogs interacting with SRIF receptor (SSTR) subtypes SSTR2 and SSTR5 reduce hormone secretion of pituitary adenomas, but their antiproliferative effects are still controversial. We investigated the in vitro effects of SRIF and SSTR-selective agonists interacting with SSTR1 (BIM-23926), SSTR2 (BIM-23120), SSTR5 (BIM-23206), or both SSTR2 and SSTR5 (BIM-23244) on alpha-subunit and chromogranin A secretion and on cell viability of 12 nonfunctioning pituitary adenomas (NFA) expressing SSTR1, SSTR2, and SSTR5, as assessed by RT-PCR. Treatment with SRIF or BIM-23206 did not modify alpha-subunit and chromogranin A secretion, which was significantly inhibited by BIM-23926, BIM-23120, and BIM-23244. SRIF and BIM-23120 did not influence cell viability, which was significantly promoted by BIM-23206 and BIM-23244 and reduced by treatment with BIM-23926. These results demonstrate that, in the selected NFA, the SSTR1-selective agonist inhibits secretory activity and cell viability, the SSTR2-selective agonist inhibits secretion but not cell viability, and the SSTR5-selective agonist does not influence secretion but promotes cell viability. These data can explain the lack of inhibitory effects of currently used SRIF analogs and suggest that drugs acting potently and preferentially on SSTR1 might be useful for medical treatment of NFA. |
| تدمد: | 1945-7197 0021-972X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adfb1f4d5c3ad7143541d194b9d150cdTest https://doi.org/10.1210/jc.2003-031954Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....adfb1f4d5c3ad7143541d194b9d150cd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19457197 0021972X |
|---|